| Literature DB >> 24852050 |
Marco Coral-Almeida1, Richar Rodríguez-Hidalgo2, Maritza Celi-Erazo3, Héctor Hugo García4, Silvia Rodríguez5, Brecht Devleesschauwer6, Washington Benítez-Ortiz7, Pierre Dorny8, Nicolas Praet9.
Abstract
BACKGROUND: Human cysticercosis is a zoonotic disease causing severe health disorders and even death. While prevalence data become available worldwide, incidence rate and cumulative incidence figures are lacking, which limits the understanding of the Taenia solium epidemiology. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2014 PMID: 24852050 PMCID: PMC4031064 DOI: 10.1371/journal.pntd.0002887
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Figure 1Sera availability and individual participation during the three sampling rounds.
(Format adapted from Mwape et al., 2013). S1, S2 and S3 stand for first, second and third sampling rounds, Ag-ELISA: Enzyme Linked ImmunosSorbent Assay for the detection of circulating antigens of the metacestode of T. solium, EITB: Enzyme-Linked Immunoelectrotransfer Blot for the detection of antibodies directed against seven specific T. solium metacestode glycoproteins.
Antigen and antibody seroprevalence figures (as based on the results of the Ag-ELISA and the EITB, respectively) by sex and by sampling round.
| Seroprevalence | Sampling round | Sex | Number of positive cases/Total number of individuals | Percentage of positive cases [95%CI] |
|
| SR 1 | Female | 2/367 | 0.5 [0.1–2] |
| Male | 5/377 | 1.3 [0.4–3.1] | ||
| Total | 7/744 | 0.9 [0.4–1.9] | ||
| SR 2 | Female | 1/293 | 0.3 [0–1.9] | |
| Male | 4/245 | 1.6 [0.4–4.1] | ||
| Total | 5/538 | 0.9 [0.3–2.2] | ||
| SR 3 | Female | 3/265 | 1.1 [0.2–3.3] | |
| Male | 5/249 | 2 [0.7–4.6] | ||
| Total | 8/518 | 1.5 [0.7–3] | ||
|
| SR 1 | Female | 124/364 | 34.1 [29.2–39.2] |
| Male | 108/379 | 28.5 [24–33.3] | ||
| Total | 232/743 | 31.2 [27.9–34.7] | ||
| SR 2 | Female | 100/293 | 34.1 [28.7–39.9] | |
| Male | 83/245 | 33.9 [28–40.2] | ||
| Total | 183/538 | 34 [30–38.2] | ||
| SR 3 | Female | 80/270 | 29.6 [24.2–35.5] | |
| Male | 77/248 | 31 [25.3–37.2] | ||
| Total | 157/518 | 30.3 [26.4–34.5] |
CI = Binomial exact 95% Confidence Intervals; SR = sampling round;
SR 1 = June 2009 sampling,
SR 2 = November 2009 Sampling;
SR 3 = July 2010 Sampling.
Proportions of antigen and antibody positive and/or negative individuals who participated in the 3 sampling rounds.
| Test result per sampling round | Number of individuals (antibody detection) | Percentage of individuals (antibody detection; [95%CI] | Number of individuals (antigen detection) | Percentage of individuals (antigen detection; [95%CI] | ||
| SR 1 | SR 2 | SR 3 | ||||
| − | − | − | 169 | 61 [54.99–66.7] | 276 | 99.63 [98–99.99] |
| − | − | + | 9 | 3.24 [1.49–0.6] | 1 | 0.36 [0.01–1.99] |
| − | + | − | 8 | 2.89 [1.25–5.61] | 0 | … |
| − | + | + | 9 | 3.24 [1.49–6.07] | 0 | … |
| + | − | − | 13 | 4.69 [2.52–7.89] | 0 | … |
| + | − | + | 4 | 1.44 [0.36–3.66] | 0 | … |
| + | + | − | 14 | 5.05 [2.79–8.33] | 0 | … |
| + | + | + | 51 | 18.4 [14.02–23.49] | 0 | … |
|
| 277 | 277 | ||||
CI = Binomial exact 95% Confidence Intervals; SR = sampling round;
SR 1 = June 2009 sampling,
SR 2 = November 2009 Sampling;
SR 3 = July 2010 Sampling.
Antigen change to seropositivity/seronegativity test result, antibody seroconversions/seroreversion figures (as based on the results of Ag-ELISA and EITB respectively) by period.
| Test | Period | Parameter | Number of individuals | Percentage of individuals ([95%CI] |
|
| P1 | Change to seropositivity for 6 months | 0/421 | 0 [0–0.9] |
| Change to seronegativity for 6 months | 0/3 | 0 [0–70.8] | ||
| P2 | Change to seropositivity for 7 months | 1/317 | 0.3 [0–1.7] | |
| Change to seronegativity for 7 months | 0/1 | 0 [0–97.5] | ||
| P3 | Change to seropositivity for 13 months | 2/373 | 0.5 [0.1–1.9] | |
| Change to seronegativity for 13 months | 1/1 | 1 [2.5–100] | ||
|
| P1 | Seroconversions | 26/288 | 9 [6–12.9] |
| Seroreversions | 25/135 | 18.5 [12.4–26.1] | ||
| P2 | Seroconversions | 17/226 | 7.5 [4.4–11.8] | |
| Seroreversions | 26/101 | 25.7 [17.6–35.4] | ||
| P3 | Seroconversions | 24/264 | 9.1 [5.9–13.2] | |
| Seroreversions | 34/120 | 28.3 [20.5–37.3] |
CI = Binomial exact 95% Confidence Intervals;
CI = one-sided, 97.5% confidence interval;
P1 = June–November period;
P2 = November–July period;
P3 = June–July period.
Yearly incidence rates for infection and exposure (as based on the results of Ag-ELISA and EITB, respectively) of individuals who participated in two sampling rounds by period.
| Test | Period between samplings | Number of individuals | Yearly incidence rate ([95% Poisson CI] |
|
| P1 | 0/421 | 0[0–1790.7] |
| P2 | 1/317 | 541.6[13.7–3018] | |
| P3 | 2/373 | 496.3 [60.1–1792.7] | |
|
| P1 | 26/288 | 18,909.1[12,352–27,706.2] |
| P2 | 17/226 | 13,399[7,805.4–21,453.1] | |
| P3 | 24/264 | 8,791.2[5,632.7–13,080.6] |
CI = Poisson exact 95% Confidence Intervals;
P1 = June–November period;
P2 = November–July period;
P3 = June–July period.
Figure 2Proportions of Ab seroconversion and seroreversion by time period.
White bars represent proportions of Ab seroconversion whereas grey bars represent proportions of Ab seroreversion; vertical error bars represent the upper and lower limits for the 95% binomial exact confidence interval; Period 1 stands for the period between Sampling round 1 and sampling round 2 (June–November 2009); Period 2 stands for the period between sampling round 2 and sampling round 3 (November 2009–July 2010) and Period 3 stands for the period between sampling round 1 and sampling round 3 (June 2009–July 2010).
Figure 3Results of the change point analysis with a change point at 30 years old.
The vertical dotted/lined line represents the change point at 30 years old; white bars represent proportions of Ab seroconversion whereas grey bars represent proportions of Ab seroreversion; vertical error bars represent the upper and lower limits for the 95% binomial exact confidence interval.